单光子核素标记的 PSMA 小分子抑制剂在前列腺癌中的临床应用进展  

Research progress in the clinical appliaction of single photon nuclide-labeled PSMA small molecule inhibitors in prostate cancer

作　　者：侯露 弓健[1] 王璐[1] 徐浩[1] Hou Lu;Gong Jian;Wang Lu;Xu Hao(Department of Nuclear Medcine,the First Affiliated Hospital of Jinan University,Guangzhou 510632,China)

机构地区：[1]暨南大学附属第一医院核医学科,广州510632

出　　处：《国际放射医学核医学杂志》2020年第11期709-716,共8页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：前列腺特异膜抗原(PSMA)在前列腺癌中特异性过表达,以其作为生物靶点,为前列腺癌的临床诊断和治疗提供了新的策略。目前,对PSMA小分子抑制剂标记的研究多集中于应用正电子核素如^(68)Ga、^(18)F等进行标记并通过PET显像实现对前列腺癌的诊断,或应用β放射性核素如^(177)Lu进行标记以靶向治疗前列腺癌。近年来,应用单光子核素标记PSMA小分子抑制剂的研究也取得了进展。笔者就单光子核素标记的PSMA小分子抑制剂在前列腺癌中的临床应用进展进行综述。Prostate-specific membrane antigen(PSMA),highly expressed in prostate cancer,provides a new strategy for the clinical diagnosis and treatment of prostate cancer as a specific biological target.At present,the research on the labeling of PSMA small molecule inhibitors is mostly focused on positron nuclide labels,such as^(68)Ga and^(18)F or beta radionuclide labels,such as^(177)Lu to realize diagnosis and targeted therapy of prostate cancer.In recent years,the application of single photon nuclidelabeled PSMA small molecule inhibitors has also made progress.This review summarizes the clinical application of single photon nuclide-labeled PSMA small molecule inhibitors in prostate cancer.

关 键 词：前列腺肿瘤 前列腺特异膜抗原 体层摄影术 发射型计算机 单光子 放射性核素显像 放射性核素治疗 

分 类 号：R737.25[医药卫生—肿瘤]